Literature DB >> 14570093

Supportive care management of brain metastases: what is known and what we need to know. Conference proceedings of the National Cancer Institute of Canada (NCIC) Workshop on Symptom Control in Radiation Oncology.

M N Tsao1, K Sultanem, D Chiu, F Copps, P Dixon, D Easton, P Haddad, C Hayter, D Hoegler, R Wong.   

Abstract

OBJECTIVES: To review the results of published randomised controlled trials in the treatment of brain metastases and, from the knowledge gained from these trials, to identify potential study questions.
MATERIALS AND METHODS: The literature was searched for randomised controlled trials that dealt with the management of brain metastases. Potential research questions were identified on the basis of the results of the literature review.
RESULTS: A number of research questions were identified. In the context of the NCIC Symptom Control Group, a trial of supportive care alone vs supportive care and whole-brain radiotherapy (WBRT) in a subset of patients with the diagnosis of brain metastases was deemed to be of highest priority. We discussed a number of issues relating to the feasibility of such a trial.
CONCLUSIONS: The optimal management of brain metastases remains elusive. Despite the results of numerous randomised controlled trials, many questions remain unanswered. The magnitude of benefit using WBRT above supportive care alone is uncertain. A trial of supportive care alone vs supportive care and WBRT may be successful once target population, feasibility and methodological issues are thoroughly solved.

Entities:  

Mesh:

Year:  2003        PMID: 14570093     DOI: 10.1016/s0936-6555(03)00220-6

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  3 in total

Review 1.  Value of 11C-methionine PET in imaging brain tumours and metastases.

Authors:  Andor W J M Glaudemans; Roelien H Enting; Mart A A M Heesters; Rudi A J O Dierckx; Ronald W J van Rheenen; Annemiek M E Walenkamp; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-12       Impact factor: 9.236

Review 2.  Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.

Authors:  Marc C Chamberlain; Christina S Baik; Vijayakrishna K Gadi; Shailender Bhatia; Laura Q M Chow
Journal:  Neuro Oncol       Date:  2017-01       Impact factor: 12.300

3.  Brain metastasis in pancreatic cancer.

Authors:  Johannes Lemke; Jan Scheele; Thomas Kapapa; Christian Rainer Wirtz; Doris Henne-Bruns; Marko Kornmann
Journal:  Int J Mol Sci       Date:  2013-02-19       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.